SEARCH

Search any criteria by typing into the box above or browse from the links below.
Click on drug name or to access monograph.

Oral liquid bottle $24.67, Tablet $0.31, Vial $2.16

Haloperidol

Editor: Updated Class:

ADMINISTRATION ROUTES:

IV, IM, PO

ALTERNATIVE NAMES:

Serenace

Note: this monograph does not apply to Haldol (Haloperidol decanoate) which has an extended duration of action, is administered by IM depot injection and is not used in ICU

ICU INDICATIONS:

  1. Delirium
  2. Psychosis

PRESENTATION AND ADMINISTRATION:

IV:

Haloperidol 5 mg in 1 mL (solution)

Administer slowly over 1-2 minutes or as a bolus, undiluted or diluted in 5-10 mL of Normal saline

May be diluted in compatible IV fluid and administered over 10-30 mins

Undiluted solution may discolour if exposed to light. Discoloured solutions should not be used

Compatible with the following IV fluid subject to concentration limits:

Normal saline (up to a concentration of 0.75 mg/mL), 5% dextrose (up to a concentration of 3 mg/mL), Glucose and sodium chloride (up to a concentration of 1 mg/mL), Hartmanns (up to a concentration of 1 mg/mL)

Store at room temperature and protect from light

PO:

Tablets:

Serenace 0.5mg tablets (green), Serenace 1.5mg (white), Serenace 5mg (red)

Liquid:

Serenace 2 mg/mL (20 drops is equal to 1 mL)

DOSAGE:

IV/IM:

ICU delirium and psychosis

0.5 mg - 10 mg as required

Usual maximum daily dose 100 mg although much higher doses have been described

PO:

0.5 mg - 20 mg as required

Usual maximum daily dose is 100 mg although much higher doses have been described

DOSAGE IN RENAL FAILURE AND RENAL REPLACEMENT THERAPY:

Dose in renal impairment

GFR (ml/min) DOSE
<10 Start with lower doses unless only giving single dose. Accumulates with repeated dosage
10-20 Dose as in normal renal function
>20-50 Start with lower doses unless only giving single dose. Accumulates with repeated dosage

Dose in renal replacement therapy

MODALITY DOSE
CAPD Start with lower doses unless only giving single dose. Accumulates with repeated dosage
HD Start with lower doses unless only giving single dose. Accumulates with repeated dosage
CVVHDF Dose as in normal renal function

DOSAGE IN PAEDIATRICS:

IV, IM, PO:

0.01 mg/kg daily, increased to 0.1 mg/kg BD

CLINICAL PHARMACOLOGY:

Haloperidol is the first of the butyrophenone series of major tranquilisers. The precise mechanism of action has not been clearly established

CONTRAINDICATIONS:

  1. Hypersensitivity to haloperidol

  2. Parkinson’s disease

WARNINGS:

Tardive Dyskinesia

A syndrome consisting of potentially irreversible, involuntary, dyskinetic movements may develop in patients treated with antipsychotic drugs. The syndrome usually develops with high doses given over a prolonged period; however, it can develop, although much less commonly, after relatively brief treatment periods at low doses.

Neuroleptic Malignant Syndrome (NMS)

A potentially fatal symptom complex referred to as Neuroleptic Malignant Syndrome (NMS) has been reported in association with antipsychotic drugs.

PRECAUTIONS:

General:

Haloperidol may lower the seizure threshold

Severe neurotoxicity (rigidity, inability to walk or talk) may occur in patients with thyrotoxicosis who are also receiving antipsychotic medication, including haloperidol.

Laboratory Tests:

No tests in addition to routine ICU tests are required

Drug/Laboratory Test Interactions: None noted

IMPORTANT DRUG INTERACTIONS IN ICU:

Combined Use of Haloperidol and Lithium

An encephalopathic syndrome (characterised by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus haloperidol. A causal relationship between these events and the concomitant administration of lithium and haloperidol has not been established; however, patients receiving such combined therapy should be monitored closely for early evidence of neurological toxicity and treatment discontinued promptly if such signs appear

ADVERSE REACTIONS:

Body as a Whole:

Neuroleptic malignant syndrome (NMS), hyperpyrexia and heat stroke have been reported with haloperidol

Central Nervous System:

Extrapyramidal Symptoms (EPS), tardive dyskinesia, insomnia, restlessness, anxiety, euphoria, agitation, drowsiness, depression, lethargy, headache, confusion, vertigo, grand mal seizures, exacerbation of psychotic symptoms including hallucinations, and catatonic-like behavioural states

Cardiovascular:

Tachycardia, hypotension, hypertension and ECG changes including prolongation of the Q-T interval and torsades de pointes

Haematological:

Mild and usually transient leukopaenia and leukocytosis, minimal decreases in red blood cell counts, anaemia, or a tendency toward lymphomonocytosis. Agranulocytosis has rarely been reported to have occurred with the use of haloperidol, and then only in association with other medication

Endocrine Disorders:

Lactation, breast engorgement, mastalgia, menstrual irregularities, gynaecomastia, impotence, increased libido, hyperglycaemia, hypoglycaemia and hyponatraemia

Gastrointestinal Effects:

Anorexia, constipation, diarrhoea, hypersalivation, dyspepsia, jaundice, nausea and vomiting

Autonomic Reactions:

Dry mouth, blurred vision, urinary retention, diaphoresis and priapism

Respiratory Effects:

Laryngospasm, bronchospasm and increased depth of respiration